Stevanato Group, Owen Mumford to collaborate on Aidaptus auto-injector

[Image from Owen Mumford]Stevanato Group (NYSE:STVN) announced today that it signed an exclusive agreement with Owen Mumford for its auto-injector technology.

Piombino Dese, Italy-based Stevanato Group’s agreement makes it an exclusive manufacturing partner for Owen Mumford’s Aidaptus auto-injector. Under the agreement, Stevanato Group will mold the components for the technology and provide final and sub-assembly equipment, along with market-leading pre-filled syringes.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Stevanato Group, Bexson expand partnership for wearable drug delivery device

[Image from Stevanato Group]Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration.

Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder (PTSD).

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Stevanato Group acquires facility set to become manufacturing hub in China

[Image from Stevanato Group]Stevanato Group (NYSE:STVN) announced today that it acquired a facility in Zhangjiagang, China, for a new manufacturing plant.

Piombino Dese, Italy-based Stevanato Group expects to begin renovations on the facility in the spring of 2022 as it works to expand in China with a new manufacturing hub for drug containment, drug delivery and diagnostic development.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Stevanato Group extends licensing agreement with Haselmeier for pen injector tech

[Image from Stevanato Group]Stevanato Group (NYSE:STVN) announced today that it signed an extension to a licensing agreement with Haselmeier over its pen injector technology.

Piombino Dese, Italy-based Stevanato Group’s license extension gives the company exclusivity to offer the Axis-D pen injector technology in support of a broader range of drugs for its biopharma customers beyond diabetes, including areas such as obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological disorder, arthritis and more.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump

Bexson is developing a wearable infusion pump with Stevanato Group. [Image from Bexson]Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy.

Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Stevanato Group expands corporate headquarters

[Image from Stevanato Group]Stevanato Group (NYSE:STVN) announced today that it expanded its corporate headquarters with a new facility in Italy.

Based in Piombino Dese, Italy, Stevanato Group expects its 6,750-square meter facility to support the optimization of its industrial footprint while advancing operations and growth within the company.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Stevanato Group beats The Street in Q3, raises guidance

Stevanato Group (NYSE:STVN) shares hit a snag today despite third-quarter results that beat the consensus forecast.

The Piombino Dese, Italy-based drug delivery technology developer posted profits of $21.6 million, or 8¢ per share, on sales of $248.6 million for the three months ended Sept. 30, 2021, for a 12.5% bottom-line gain on sales growth of 36.5%.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Stevanato Group is constructing a new facility in Indiana

Stevanato Group (NYSE:STVN) announced today that it will begin construction on a new U.S. facility in Fishers, Indiana.

Piombino Dese, Italy-based Stevanato Group will begin construction on the new facility this month with expectations for the site to be operational in 2023.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

MedTech 100 roundup: On the rise again

After a slight hiccup disrupted weeks of improvement, the medtech industry again flexed its muscles over the last seven days.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 20) at 119.63 points, representing a 1.5% rise from the 117.92-point tally set a week prior.

The shift marks a quick rebound from the -1.2% dip observed in the previous week and the index now sits at its highest week-ending mark ever, having actually hit an all-time best of 119.72 points on Aug. 17.

Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry remains well above the marks set around the height of the pandemic, having registered a 29.6% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). Moreover, it remains well ahead of the mid-pandemic low of 62.13 (March 23, 2020) as well, totaling an 92.5% asc…

Read more
  • 0

Stevanato Group brings in upsized IPO worth $453.5M

Stevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares.

The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0